How Has the Attention Deficit Hyperactivity Disorder Market Evolved Historically and What is its Current Size?
The attention deficit hyperactivity disorder market has seen considerable growth due to a variety of factors.
• The market size for attention deficit hyperactivity disorder has seen vigorous growth in recent years. Projected to rise from $16.29 billion in 2024 to $17.43 billion in 2025, the market will experience a compound annual growth rate (CAGR) of 7.0%.
The historical period growth can be credited to an increased occurrence of ADHD, a rise in childhood ADHD cases, growing knowledge about ADHD, augmented health care spending, and governmental initiatives for mental health consciousness.
What Is The Projected Growth Of The Attention Deficit Hyperactivity Disorder Market Size In The Coming Years?
The attention deficit hyperactivity disorder market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of attention deficit hyperactivity disorder is predicted to experience significant growth in the upcoming years, reaching $22.59 billion in 2029 with a compound annual growth rate of 6.7%.
This expansion during the projected period could be a result of a rise in the number of pediatric and adult patients being treated, enhanced healthcare facilities, the rising implementation of personalized medicine, increasing recognition of mental health issues, and a growing trend of using additives and preservatives in children's food. Key trends expected to be seen during the forecast period are technological advancements and innovative treatment methods, progress in diagnostics and treatment procedures, the creation of new therapeutic medications, a movement towards non-stimulant drugs, and advancements in pharmaceutical treatments.
What Are the Critical Driver Fuelling The Attention Deficit Hyperactivity Disorder Market's Growth?
The rapid rise in the uptake of personalized medicine is anticipated to fuel the expansion of the attention deficit hyperactivity disorder (ADHD) market. This model of medicine customizes healthcare interventions based on a patient's genetic, environmental, and lifestyle attributes, achieving more precision and efficacy. The increased use of personalized medicine is attributed to advancements in genomics technologies that allow a patient's treatment plan to align with their genetic makeup, leading to more targeted and successful therapy. The impact of ADHD in the realm of personalized medicine is considerable, enabling the development of tailor-made treatment plans that account for an individual's distinct genetic, environmental, and behavioral traits, leading to more successful and personalized interventions. A report published by the Personalized Medicine Coalition (PMC), a US-based charitable organization, in February 2024, stated that personalized medicines were responsible for over a third of newly approved FDA drugs for the fourth year in a row in 2023. The FDA granted approval to 16 new personalized treatments for rare diseases (an increase from 6 in 2022), 7 cancer drugs, and 3 for additional conditions. As a result, the rising adoption of personalized medicine contributes significantly to the expansion of the ADHD market.
What Are The Principal Market Segments In The Global Attention Deficit Hyperactivity Disorder Industry?
The attention deficit hyperactivity disorder market covered in this report is segmented –
1) By Type: Stimulants, Non-Stimulants
2) By Age Group: Children, Adults
3) By Gender: Male, Female
4) By Dosage Form: Tablets, Capsules, Other Dosage Forms
5) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy
Subsegments:
1) By Stimulants: Methylphenidate-based Medications, Amphetamine-based Medications, Mixed Amphetamine Salts, Dexmethylphenidate
2) By Non-Stimulants: Atomoxetine (Strattera), Guanfacine (Intuniv), Clonidine (Kapvay), Bupropion (Wellbutrin)
Pre-Book The Attention Deficit Hyperactivity Disorder Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Attention Deficit Hyperactivity Disorder Industry?
Leading corporations involved in the attention deficit hyperactivity disorder (ADHD) market are developing novel medicines such as extended-release capsules to enhance therapeutic effectiveness, increase patient adherence, and provide sustained symptom relief. These extended-release capsules slowly release the medication over a period, offering steady symptom management all day with just one dosage, thereby reducing the necessity for multiple dosages and enhancing the convenience and adherence to the treatment regime for those suffering from ADHD. For example, in February 2022, Guanfacine XR, a generic equivalent of Takeda Canada Inc.'s drug INTUNIV XR, intended for ADHD treatment, was introduced by JAMP Pharma Group, a pharmaceutical firm based in Canada. As a long-lasting form of guanfacine, the drug functions by influencing specific brain receptors to help manage attention, impulse control, and hyperactivity. The medication is offered in various strengths (1 mg, 2 mg, 3 mg, and 4 mg) and is packaged in a 100-count bottle, thus providing treatment flexibility.
Who Are the Key Players In The Attention Deficit Hyperactivity Disorder Market?
Major companies operating in the attention deficit hyperactivity disorder market are:
• Pfizer Inc.
• Johnson & Johnson
• AstraZeneca PLC
• Novartis International AG
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Supernus Pharmaceuticals Inc.
• Neos Therapeutics Inc.
• Collegium Pharmaceutical Inc.
• Mallinckrodt Pharmaceuticals plc
• Tris Pharma Inc.
• Arbor Pharmaceuticals LLC
• Akili Interactive Labs Inc.
• Mind Medicine (MindMed) Inc.
• NeuroSigma Inc.
• KemPharm Inc.
• RespireRx Pharmaceuticals Inc.
• Cingulate Therapeutics LLC
• Adlon Therapeutics L.P.
What Are The Regional Insights Into The Attention Deficit Hyperactivity Disorder Market?
North America was the largest region in the attention deficit hyperactivity disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
